1. Home
  2. CD vs CUVL Comparison

CD vs CUVL Comparison

Compare CD & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chaince Digital Holdings Inc. Ordinary Shares

CD

Chaince Digital Holdings Inc. Ordinary Shares

SELL

Current Price

$7.04

Market Cap

323.4M

Sector

Technology

ML Signal

SELL

Logo Clinuvel Pharmaceuticals Limited American Depositary Shares

CUVL

Clinuvel Pharmaceuticals Limited American Depositary Shares

N/A

Current Price

$5.04

Market Cap

374.2M

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
CD
CUVL
Founded
2011
1999
Country
United States
Australia
Employees
N/A
16
Industry
Computer Software: Programming Data Processing
Miscellaneous
Sector
Technology
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
323.4M
374.2M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
CD
CUVL
Price
$7.04
$5.04
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 263.3K
7.2K
Earning Date
08-31-2023
08-27-2026
Dividend Yield
N/A
★ 0.56%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $1,867,068.00
N/A
Revenue This Year
N/A
$0.89
Revenue Next Year
N/A
$6.69
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 277.93
N/A
52 Week Low
$2.10
$4.91
52 Week High
$14.10
$8.20

Technical Indicators

Market Signals
Indicator
CD
CUVL
Relative Strength Index (RSI) 55.42 35.18
Support Level $4.86 N/A
Resistance Level $8.89 $6.04
Average True Range (ATR) 1.60 0.14
MACD -0.17 -0.03
Stochastic Oscillator 25.72 29.82

Price Performance

Historical Comparison
CD
CUVL

About CD Chaince Digital Holdings Inc. Ordinary Shares

Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.

About CUVL Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.

Share on Social Networks: